In a significant boost to India’s self-reliance in healthcare, Union Health Minister JP Nadda inaugurated the indigenously developed Tetanus and Adult Diphtheria (TD) vaccine at the Central Research Institute (CRI) in Kasauli, Himachal Pradesh. This milestone event marks the first time CRI has launched a homegrown TD vaccine, reinforcing the nation’s vaccine manufacturing capabilities.
Nadda hailed the achievement as a cornerstone in strengthening public health infrastructure. Speaking at the launch, he praised the CRI team for their dedication and emphasized how this vaccine exemplifies the government’s commitment to Atmanirbhar Bharat in the health sector. ‘This launch signifies our resolve towards self-sufficiency,’ Nadda stated, highlighting that India has now achieved 99% vaccination coverage, a feat drawing global attention.
The minister outlined ambitious plans, noting that CRI will supply 5.5 million doses to the Universal Immunization Programme by April 2026, with production ramping up progressively. He commended Prime Minister Narendra Modi’s vision, crediting state governments’ tireless efforts in meeting health and pharmaceutical self-reliance goals.
Nadda reminded the audience of India’s stature as the ‘world’s pharmacy,’ with the country ranking third in WHO regulatory systems. He contrasted historical vaccine development timelines—decades for tetanus and tuberculosis drugs, a century for Japanese Encephalitis—with India’s rapid response to COVID-19, developing two indigenous vaccines in nine months and administering over 220 crore doses, including boosters, via digital certificates.
This TD vaccine launch not only bolsters routine immunization but also positions India as a leader in affordable, accessible healthcare solutions for the world.